Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.
Hernández
José-Angel
JA
Department of Hematology, Hospital de Mataró, Mataró, Barcelona, Spain. jahernandez@csm.scs.es
Diloy
Raúl
R
Salat
David
D
del Río
Neus
N
Martínez
Xavier
X
Castellví
Josep-María
JM
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D009154:Mutation; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D019259:Lamivudine; D000069283:Rituximab